RefleXion Medical   Report issue

For profit Phase 1
Founded: Hayward CA United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2018
NCT03493789
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

RefleXion Medical

Active Ingredients

Drugs in Phase 1 Trials (1)

fludeoxyglucose f-18 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1